Asahina Y, et al. - The physicians aimed to evaluate the efficacy of a ribavirin-free regimen of ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus (HCV) genotype 2 infection. Twelve weeks of treatment with ledipasvir-sofosbuvir resulted in high rates of sustained virologic response 12 weeks after therapy (SVR12) that were non-inferior to sofosbuvir + ribavirin, among Japanese patients with HCV genotype 2.